- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05181865
Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors
A Phase 1/2a, First-In-Human, Open Label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FL-301 in Patients With Advanced Solid Tumors
Study Overview
Status
Conditions
Detailed Description
This is a Phase 1/2a, first-in-human, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of FL-301 in patients with advanced cancer. The study will consist of 2 phases, Phase 1 and Phase 2a.
In Phase 1, dose escalation will proceed according to a rule-based design methodology. Phase 1 will explore dosing in which a single dose of FL-301 is administered by intravenous (IV) infusion every 2 weeks (Q2W) in 4-week cycles. Patients with measurable advanced solid tumors expressing claudin 18.2 may be enrolled, with the cutoff levels further defined in the eligibility criteria. Dose escalation methodology (modified 3+3 design) will utilize prespecified dose increments.
Once the RP2D has been established, Phase 2a will commence to explore preliminary evidence of antitumor efficacy and confirm the safety of FL-301. The dosing schedule will be explored in up to 3 separate patient groups of approximately 30 patients per group.
Group 1 will include patients with pancreatic cancer; Group 2 will include patients with gastric cancer (including gastroesophageal junction [GEJ]); and Group 3 will include patients with any other solid tumor (primarily non-small cell lung cancer [NSCLC], ovarian, and cholangiocarcinoma with claudin 18.2 expression).
Response and progression will be evaluated in this study using computerized tomography (CT) or magnetic resonance imaging (MRI) imaging per RECIST v1.1. Long-term follow-up (survival and disease status, as applicable) will be conducted up to 18 months or until death, start of new anticancer therapy, end of study, or withdrawal of consent, whichever occurs first.
Study Type
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
General Inclusion Criteria
Applicable to all patients in both the Phase 1 and Phase 2a parts of the study:
- Histological or cytologically confirmed locally advanced or metastatic solid tumor
- Life expectancy >12 weeks.
- Age ≥18 years.
- ECOG performance status 0 or 1 at screening.
- Fully vaccinated against COVID-19 at least 3 weeks before C1D1. If under consideration for a booster, the booster administration needs to be complete within the same time constraint (ie, at least 3 weeks before C1D1).
Adequate organ function, defined as:
- Hematology: defined as absolute neutrophil count (ANC) ≥1.5×109/L, platelet ≥90×109/L, hemoglobin ≥9.0 g/dL (in the absence of transfusion and use of growth factors within the last 14 days of screening labs).
- Renal function defined as calculated creatinine clearance (CCr) or radioisotope glomerular filtration rate >60 mL/min/1.73 m2 calculated by Cockcroft-Gault formula or normal serum creatinine with a maximum serum creatinine of 1.5 mg/dL.
Hepatic Function:
- Alanine aminotransferase (ALT) ≤2.5 × ULN; ≤5 × ULN if with liver metastases.
- Total bilirubin ≤1.5×ULN.
Serum Electrolytes:
- Serum potassium, calcium, magnesium, and phosphate within normal limits or not worse than CTCAE v5.0 Grade 1 and asymptomatic. If values are low on the initial screening assessment, supplements may be given, if clinically appropriate, and values repeated to confirm within CTCAE v5.0 Grade 1 limits.
Specific criteria for Phase 1:
- Positive claudin 18.2 tumor expression defined as ≥50% of tumor cells demonstrating moderate-to-strong membranous staining (2+/3+) by IHC assay performed on sections of tumor derived from formalin fixed paraffin block.
- Pathological diagnosis (histological) of any solid tumor cancer with positive claudin 18.2 tumor expression as defined above.
Specific criteria for Phase 2a:
- Positive claudin 18.2 tumor expression defined as ≥70% of tumor cells demonstrating moderate-to-strong membranous staining (2+/3+) by IHC assay performed on sections of tumor derived from formalin fixed paraffin block.
- At least 1 measurable target lesion as defined by RECIST 1.1
Disease progression or relapse following conventional chemotherapy, patient must have documented radiological progression during or after their most recent anticancer therapy:
- Pancreatic cancer: Patient should have received at least one but no more than two systemic therapies for their metastatic diseases
- Gastric cancer (including GEJ cancer): Patient should have received at least two but no more than three systemic therapies for their metastatic diseases;
- Other solid tumor cancers: Patients with other solid tumors who have no standard therapies available
Exclusion Criteria
Patients who meet any of the following criteria will be excluded:
- History of severe infusion reaction with monoclonal antibody treatment.
- Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening.
- Known history of HIV.
- Serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
- Presence of other active cancers, or history of treatment for invasive cancer ≤3 years. Patients with Stage I cancer who have received definitive local treatment and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (ie, noninvasive) are eligible, as are patients with history of nonmelanoma skin cancer.
- Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
- Active central nervous system (CNS) disease involvement, defined by cerebrospinal fluid (CSF) cytology, magnetic resonance imaging (MRI) or computerized tomography (CT); patients with asymptomatic CNS metastases are eligible if they have been clinically stable for at least 4 weeks prior to the first dose of study drug and do not require interventions such as surgery, radiation or any corticosteroid therapy for management of symptoms related to CNS disease.
- Pregnant or nursing (lactating) women (Appendix B).
- Patients who received claudin 18.2 targeting agents previously.
Prior radiotherapy:
- Non-CNS site of radiation must be completed >2 weeks prior to FL-301 infusion
- CNS directed radiation must be completed >4 weeks prior to FL-301 infusion as long as patients are asymptomatic post radiation therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Phase 1 - Cohort 1
|
N = 1
Other Names:
|
EXPERIMENTAL: Phase 1 - Cohort 2
|
N = 3-6
Other Names:
|
EXPERIMENTAL: Phase 1 - Cohort 3
|
N = 3-6
Other Names:
|
EXPERIMENTAL: Phase 1 - Cohort 4
|
N = 3-6
Other Names:
|
EXPERIMENTAL: Phase 1 - Cohort 5
|
N = 3-6
Other Names:
|
EXPERIMENTAL: Phase 2a - Group 1
|
Pancreatic Cancer N = 30
Other Names:
Gastric Cancer (Including GEJ) N = 30
Other Names:
Other Solid Tumors N = 30
Other Names:
|
EXPERIMENTAL: Phase 2a - Group 2
|
Pancreatic Cancer N = 30
Other Names:
Gastric Cancer (Including GEJ) N = 30
Other Names:
Other Solid Tumors N = 30
Other Names:
|
EXPERIMENTAL: Phase 2a - Group 3
|
Pancreatic Cancer N = 30
Other Names:
Gastric Cancer (Including GEJ) N = 30
Other Names:
Other Solid Tumors N = 30
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1: The incidence of DLTs (during DLT observation period)
Time Frame: Up to 12 months
|
Determine the MTD, and/or to select an RP2D, and investigate the safety and tolerability of FL-301 in patients with advanced solid malignancies
|
Up to 12 months
|
Phase 2a (Expansion): ORR (CR + PR) assessed centrally by RECIST v1.1
Time Frame: Up to 12 months
|
Assess the preliminary antitumor efficacy of FL-301, by central RECIST v1.1
|
Up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1: Incidence of patients with TEAEs and SAEs
Time Frame: Up to 12 months
|
Characterize the safety and tolerability of FL-301
|
Up to 12 months
|
Phase 1: Incidence of patients who develop ADAs and neutralizing ADAs during treatment with FL-301
Time Frame: Up to 12 months
|
Characterize the immunogenicity of FL-301
|
Up to 12 months
|
Phase 1: ORR (CR + PR), DOR, and DCR assessed locally by RECIST v1.1
Time Frame: Up to 12 months
|
Assess the preliminary antitumor efficacy of FL-301
|
Up to 12 months
|
Phase 1: PK parameters - Cmax
Time Frame: Up to 12 months
|
Characterize the PK of FL-301
|
Up to 12 months
|
Phase 1: PK parameters - Tmax
Time Frame: Up to 12 months
|
Characterize the PK of FL-301
|
Up to 12 months
|
Phase 1: PK parameters - AUC (0-∞)
Time Frame: Up to 12 months
|
Characterize the PK of FL-301
|
Up to 12 months
|
Phase 1: PK parameters - AUC (0-τ)
Time Frame: Up to 12 months
|
Characterize the PK of FL-301
|
Up to 12 months
|
Phase 1: PK parameters - Half-life (t1/2)
Time Frame: Up to 12 months
|
Characterize the PK of FL-301
|
Up to 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1 (Exploratory): ORR (CR + PR), DOR, and DCR assessed centrally by RECIST v1.1
Time Frame: Up to 12 months
|
Assess the preliminary antitumor efficacy of FL-301
|
Up to 12 months
|
Phase 1 (Exploratory): Explore the predictive potential of biomarkers measured in blood and/or tumor tissue in response to FL-301
Time Frame: Up to 12 months
|
Explore the predictive potential of biomarkers measured in blood and/or tumor tissue in response to FL-301
|
Up to 12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FL-301-1001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on 1 mg/kg IV FL-301
-
Healthgen Biotechnology Corp.RecruitingEmphysema Secondary to Congenital AATDUnited States
-
Janssen-Cilag International NVCompleted
-
Bristol-Myers SquibbCompletedMelanomaFrance, Canada, United States, Germany, Australia, Russian Federation, Spain, Italy, Netherlands, Poland, Denmark, Israel, United Kingdom
-
AM-PharmaCompleted
-
Healthgen Biotechnology Corp.Completed
-
Rockefeller UniversityBrigham and Women's Hospital; Weill Medical College of Cornell University; University...CompletedHealthy | HIVUnited States, Germany
-
BioMarin PharmaceuticalTerminatedDuchenne Muscular DystrophyBelgium, Netherlands, Italy, Sweden
-
BioMarin PharmaceuticalTerminatedDuchenne Muscular DystrophyNetherlands, Belgium, Italy, Sweden
-
MedImmune LLCCompletedHealthy SubjectsUnited States
-
International AIDS Vaccine InitiativeBeth Israel Deaconess Medical Center; Ragon Institute of MGH, MIT and Harvard; University of Texas Health, Houston AIDS Research Team (HART) and other collaboratorsCompleted